Med City News -- Many, if not most, medical device companies perform pilot clinical studies outside of the U.S. Cost reductions, avoiding a protracted FDA Investigational Device Exemption (IDE) approval process, and the ability to make design changes during the study without continual IDE amendments are the leading reasons to perform early studies outside the U.S (OUS).
